Esogrd-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30mg and Esomeprazole 40mg, designed for the management of gastroesophageal reflux disease (GERD) and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related symptoms including heartburn and acid regurgitation. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing symptom control and improving patient compliance. Esogrd-D Capsule SR is indicated for the treatment of erosive esophagitis, non-erosive reflux disease (NERD), and prevention of acid reflux complications. It should be administered as prescribed by a healthcare professional, with caution advised in patients with hepatic impairment or known hypersensitivity to either component. Common adverse effects may include headache, dry mouth, abdominal discomfort, or dizziness. Regular monitoring and adherence to prescribed dosage are essential to optimize therapeutic outcomes and minimize potential side effects. This combination therapy offers a synergistic approach by addressing both motility and acid secretion abnormalities in GERD management.